InQueensland

NEWS •⁠ POLITICS •⁠ BUSINESS •⁠ CULTURE

Get InQueensland in your inbox Subscribe

Japan, South Korea to join Singapore in Aussie travel bubble

News

Two-way quarantine-free travel to South Korea and Japan from Australia is being considered by the prime minister as the country looks to expand international travel.

Print article

Scott Morrison said the government was working quickly to establish the arrangements between the two Asian nations, following a similar deal with Singapore.

Australians have been able to travel to Singapore from this week, while citizens from the city-state will be able to arrive without quarantining from November 21.

However, Morrison told the Victorian Chamber of Commerce and Industry caution was still needed following the return of international travel.

“We have just got to get through the next couple of weeks and Australia has been through a lot,” Morrison said.

“We don’t want to get the wobbles now in managing the safely reopening process.”

News of the potential new travel routes comes as Victoria registered 1003 new cases of Covid-19 in the latest reporting period, as well as 14 deaths.

Infections were stable in NSW with 216 new cases and three deaths reported on Wednesday.

The state surpassed a 90 per cent vaccination rate on Tuesday and Mr Morrison said the approach of eastern states with high vaccination rates should be a model for other jurisdictions.

“I commend both NSW and Victoria in abolishing quarantine for those coming from overseas, vaccination was a key part of the answer and that has to be honoured,” he said.

“It’s encouraging to other states.”

About 81 per cent of Australians aged 16 and older are fully vaccinated, while almost 90 per cent have received their first dose.

The prime minister indicated students and skilled workers would probably be allowed to travel to Australia without having to quarantine before the end of the year.

New Covid treatments could also soon enter the Australian market, with AstraZeneca asking medical regulators to approve its Evusheld antibody treatment.

It has already been given provisional determination by the Therapeutic Goods Administration, however, the long-lasting antibody is not a vaccine.

A new pill could also enter the market after British regulators approved Merck’s molnupiravir treatment for a drug trial.

Infectious diseases expert at the Australian National University, Professor Peter Collignon, said the drug looked promising.

“I think we will get it here (in Australia),” Professor Collignon told the Seven Network on Tuesday.

“It looks like they decrease the chance of you dying and decreasing hospitalisation if you get it early.”

More News stories

Loading next article